The NCCN AML prognostic stratification system listed FLT3, NPM1, CEBPA, IDH1/2, DNMT3A (DNA methyltransferase 3A), KIT, TP53 (tumor suppressor 53), RUNX1, and ASXL1 (ASXL transcription factor) gene mutations for the classification of the AML patient population [65,66]. This evidence concerns the gene RUNX1 and acute myeloid leukemia.